Pembrolizumab population PK and exposure
Reference paper ↗A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.
- Therapeutic
- Pembrolizumab
- Modality
- Monoclonal antibody
- Target
- PD-1 / PDCD1
- Disease
- Oncology indications treated with pembrolizumab
- Model type
- PopPK
Complete model workspace
Checking workspace access…
- Parameters
- 8
- States
- 4
- Equations
- 4
- Derived outputs
- 15
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
2 mg/kg every 3 weeks, 77.2 kg
How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–378 day; step 0.25
| Input | Default | Available range |
|---|---|---|
| Clearance | 0.2034 L/day | 0.1017–0.3051 L/day |
| Central volume | 3.292 L | 1.646–4.938 L |
| Intercompartmental clearance | 0.4 L/day | 0.2–0.6 L/day |
| Peripheral volume | 3.719 L | 1.86–5.579 L |
| Body weight | 77.2 kg | 38.6–115.8 kg |
Expected readouts
Central pembrolizumab concentration · Peripheral pembrolizumab concentration · Cumulative pembrolizumab exposure
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 8 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: PD-1 binding or receptor occupancy, immune response, tumor effects, and efficacy equivalence between regimens are not represented; this is two-compartment PK.
Modeled relationships (7)
- Repeated IV dosing → Central exposure: dose events (flow)
- Central exposure ↔ Peripheral pool: distribution (reversible exchange)
- Central exposure → Systemic clearance: systemic CL (loss)
- Body-weight scaling → Central exposure: scales Vc (modulation)
- Body-weight scaling → Peripheral pool: scales Q / Vp (modulation)
- Body-weight scaling → Systemic clearance: scales CL (modulation)
- Central exposure → Cumulative exposure: integrates C (production)
Modeled relationships: Repeated IV dosing to Central exposure: dose events (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Systemic clearance: systemic CL (loss); Body-weight scaling to Central exposure: scales Vc (modulation); Body-weight scaling to Peripheral pool: scales Q / Vp (modulation); Body-weight scaling to Systemic clearance: scales CL (modulation); Central exposure to Cumulative exposure: integrates C (production).
Primary readouts: Central pembrolizumab concentration; Peripheral concentration; Cumulative exposure.
Related models
Research use only — not for patient-specific prediction or dosing advice.
